- Born:
- May 6, 1922, Fürth, Ger.
- Died:
- June 20, 2009, Lansdale, Pa., U.S. (aged 87)
- Awards And Honors:
- National Medal of Science (2000)
- Subjects Of Study:
- organic chemistry
- peptide
- ribonuclease
Ralph F. Hirschmann
-
Who was Ralph F. Hirschmann?
Ralph F. Hirschmann (1922–2009) was an American chemist known for his techniques for the chemical synthesis of peptides. His work significantly impacted medicinal chemistry, leading to breakthroughs in drug development.
Born in Germany, Hirschmann's family moved to the U.S. in the late 1930s. He studied organic chemistry at the University of Wisconsin, earning a doctorate in 1950. He then joined Merck Research Laboratories, where he discovered stereoelectronic control, which concerns how electron configurations of atoms control chemical reactions.
Hirschmann directed protein research at Merck and, with Robert G. Denkwalter, developed a novel method for synthesizing ribonuclease. He later led the development of therapeutic agents, including Vasotec, Ivomec, and Proscar. After retiring from Merck, he contributed to the field of peptidomimetics at the University of Pennsylvania.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What was Ralph F. Hirschmann's main field of study?
Ralph F. Hirschmann was an American chemist renowned for his work in developing techniques for the chemical synthesis of peptides. His work significantly impacted medicinal chemistry, contributing to breakthroughs in drug development. He studied organic chemistry at the University of Wisconsin in Madison, earning a doctorate in 1950. Hirschmann's discovery of stereoelectronic control, which concerns how electron configurations of atoms control chemical reaction products, has proven fundamental to understanding organic chemistry.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What important scientific achievement is Ralph F. Hirschmann known for?
Ralph F. Hirschmann, an American chemist, is best known for his development of techniques for the chemical synthesis of peptides. His work significantly impacted medicinal chemistry, proving fundamental to breakthroughs in drug development in the late 20th and early 21st centuries.
In 1969, Hirschmann and Robert G. Denkwalter developed a novel method for the organic synthesis of an enzyme known as ribonuclease, using special protecting groups to link together short segments of amino acids known as peptides to control the synthetic reactions. In the 1990s, Hirschmann helped establish a new field of synthetic drug discovery called peptidomimetics, which involved the modification of substances to create small peptidelike compounds.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did Hirschmann's work improve the development of medicines?
Ralph F. Hirschmann is best known for his techniques for the chemical synthesis of peptides. His work significantly impacted medicinal chemistry, proving fundamental to breakthroughs in drug development in the late 20th and early 21st centuries.
Hirschmann's method for synthesizing an enzyme known as ribonuclease involved linking together short segments of amino acids known as peptides using special protecting groups to control the synthetic reactions. He also oversaw the development of multiple new therapeutic agents, including Vasotec, Ivomec, and Proscar. In the 1990s, he helped establish a new field of synthetic drug discovery called peptidomimetics, which involved the modification of substances to create small peptidelike compounds.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is peptide synthesis and why was his contribution significant?
Peptide synthesis is a method of linking short segments of amino acids known as peptides using nonreactive molecules, called protecting groups, to control synthetic reactions. Ralph F. Hirschmann, an American chemist, developed techniques for this chemical synthesis of peptides.
Hirschmann's development of techniques for peptide synthesis significantly impacted medicinal chemistry, proving fundamental to breakthroughs in drug development during the late 20th and early 21st centuries. In 1969, Hirschmann and Robert G. Denkwalter developed a novel method for the organic synthesis of an enzyme known as ribonuclease.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How has Ralph F. Hirschmann's research influenced modern chemistry and drug discovery?
Ralph F. Hirschmann's research significantly impacted medicinal chemistry, leading to breakthroughs in drug development. His work on stereoelectronic control, which explains how electron configurations control chemical reaction products, has been fundamental to understanding organic chemistry.
Hirschmann, along with Robert G. Denkwalter, developed a novel method for synthesizing peptides using protecting groups to control reactions, enabling the creation of complex molecules like the enzyme ribonuclease. Later, he helped establish peptidomimetics, modifying substances to create small, peptide-like compounds for synthetic drug discovery. His work led to the development of therapeutic agents such as Vasotec, Ivomec, and Proscar.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Ralph F. Hirschmann (born May 6, 1922, Fürth, Ger.—died June 20, 2009, Lansdale, Pa., U.S.) was an American chemist who is best known for his development of techniques for the chemical synthesis of peptides. Hirschmann’s work significantly impacted the area of medicinal chemistry, proving fundamental to breakthroughs in drug development in the late 20th and early 21st centuries.
Hirschmann was the youngest of three boys, and his father worked as a banker. In the late 1930s, following the rise to power of the Nazi Party in Germany, the Hirschmann family moved to Kansas City, Mo., U.S. Hirschmann attended Oberlin College in Ohio, where he received a bachelor of arts degree in 1943. Upon graduation he joined the U.S. Army (serving for three years), and in 1944 he became a naturalized citizen. Hirschmann then studied organic chemistry under the guidance of American chemist William S. Johnson at the University of Wisconsin in Madison, earning a doctorate degree in 1950. That same year he joined Merck Research Laboratories in New Jersey and shortly thereafter discovered that the behaviour of the products of chemical reactions is controlled by the electron configurations of the atoms within the compounds. This effect, which he called stereoelectronic control, has since proved fundamental to scientists’ understanding of organic chemistry.
In 1968 Hirschmann was promoted to director of protein research at Merck. The next year, working with American chemist Robert G. Denkwalter, Hirschmann developed a novel method for the organic synthesis of an enzyme known as ribonuclease. The method involved linking together short segments of amino acids known as peptides using special protecting groups (essentially, nonreactive molecules) to control the synthetic reactions. In the absence of protecting groups, peptides polymerize uncontrollably with nearby amino acids. The inability to restrain these reactive tendencies had thwarted the success of early attempts at peptide synthesis. At the same time that Denkwalter and Hirschmann completed their work, a team of scientists led by American chemist Bruce Merrifield at the Rockefeller Institute for Medical Research (now Rockefeller University) in New York City accomplished the same feat, but by linking together individual amino acids to create a full-length ribonuclease enzyme. (Merrifield was awarded the 1984 Nobel Prize for Chemistry for his work.)
In 1972 Hirschmann became senior director of medicinal chemistry at the Merck facility in West Point, Pa., and several years later was promoted to senior vice president of basic research for the company, directing projects at both the New Jersey and the West Point laboratories. In leading a variety of endeavours, Hirschmann oversaw the development of multiple new therapeutic agents, including Vasotec, which was used to treat high blood pressure (hypertension); Ivomec, which was used to treat parasitic infection in animals; and Proscar, which was used to treat benign prostatic hyperplasia (enlarged prostate) in men.
Hirschmann held the position of vice president of basic research until his retirement from Merck in 1987. He then taught at the University of Pennsylvania and the Medical University of South Carolina. In the 1990s, while collaborating with chemists at Pennsylvania, he helped establish a new field of synthetic drug discovery called peptidomimetics, which involved the modification of substances to create small peptidelike compounds. Hirschmann retired from his teaching duties in 2006 because of health problems.
Throughout Hirschmann’s career, he wrote or cowrote more than 200 scientific papers. He also received numerous awards and honours, including several from the American Chemical Society (ACS), such as the Alfred Burger Award in Medicinal Chemistry (1994) and the Arthur C. Cope Award (1999). He received the National Medal of Science (2000), awarded to him by U.S. Pres. Bill Clinton, and the American Institute of Chemists Gold Medal Award (2003). Hirschmann was inducted into the ACS Medicinal Chemistry Hall of Fame in 2007. An award established in his name in 1988—the ACS Ralph F. Hirschmann Award in Peptide Chemistry—was sponsored by Merck Research Laboratories and was given to individuals who make outstanding contributions to the fields of chemistry, biochemistry, or biophysics.